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A B S T R A C T
Purpose
Long-term survival rates for older patients with newly diagnosed acute myeloid leukemia (AML) are
extremely low. Previous observational studies suggest that allogeneic hematopoietic stem-cell
transplantation (HSCT) may improve overall survival (OS) because of lower rates of relapse. We sought
to prospectively determine the value of HSCT for older patients with AML in first complete remission.
Patients and Methods
We conducted a prospective multicenter phase II study to assess the efficacy of reduced-intensity
conditioning HSCT for patients between the ages of 60 and 74 years with AML in first complete
remission. The primary end point was disease-free survival at 2 years after HSCT. Secondary end
points included nonrelapse mortality (NRM), graft-versus-host disease (GVHD), relapse, and OS.
Results
In all, 114 patients with a median age of 65 years received transplantations. The majority (52%)
received transplantations from unrelated donors and were given antithymocyte globulin for GVHD
prophylaxis. Disease-free survival and OS at 2 years after transplantation were 42% (95% CI, 33%
to 52%) and 48% (95% CI, 39% to 58%), respectively, for the entire group and 40% (95% CI, 29%
to 55%) and 50% (95% CI, 38% to 64%) for the unrelated donor group. NRM at 2 years was 15%
(95% CI, 8% to 21%). Grade 2 to 4 acute GVHD occurred in 9.6% (95% CI, 4% to 15%) of
patients, and chronic GVHD occurred in 28% (95% CI, 19% to 36%) of patients. The cumulative
incidence of relapse at 2 years was 44% (95% CI, 35% to 53%).
Conclusion
Reduced-intensity conditioning HSCT to maintain remission in selected older patients with AML is
relatively well tolerated and appears to provide superior outcomes when compared with historical
patients treated without HSCT. GVHD and NRM rates were lower than expected. Future
transplantation studies in these patients should focus on further reducing the risk of relapse.
J Clin Oncol 33:4167-4175. © 2015 by American Society of Clinical Oncology
INTRODUCTION
The prognosis for patients with acute myeloid leu-
kemia (AML) who are age 60 years or older at the
time of initial diagnosis is poor.1,2 Despite first com-
plete remission (CR1) rates of up to 50% to 60%,
prospects for long-term survival after chemother-
apy are dismal because of the high risk of relapse
( 80%).2-7 Myeloablative conditioning followed
by allogeneic hematopoietic stem-cell transplanta-
tion (HSCT) is associated with significantly lower
rates of relapse compared with conventional che-
motherapy when performed in younger patients
with AML in CR1 and improves survival in
intermediate- and high-risk patients.8 Historically,
the toxicity of this approach in older patients was
considered prohibitive.9 Reduced-intensity condi-
tioning (RIC) regimens were developed to decrease
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regimen-related toxicity in older patients and in those with
comorbidities.10-12 Although preliminary results with this approach in
older patients with AML were encouraging and suggested improved
disease-free survival (DFS) rates, most published reports were retro-
spective and were based on single-institution experiences with a wide
variety of regimens.13,14 We sought to determine the effectiveness of a
uniform RIC transplantation regimen in older patients with AML in
CR1 and available HLA-matched related or unrelated donors on a
prospective multicenter phase II trial conducted by the Alliance for
Clinical Trials in Oncology (formerly Cancer and Leukemia Group B
[CALGB]) and the Blood and Marrow Transplant Clinical Trial Net-
work. We show RIC-based HSCT to be an effective strategy for suit-
able older patients with an available matched donor.
PATIENTS AND METHODS
Patients and Donors
Patients from age 60 to 74 years with a diagnosis of AML in CR1 accord-
ing to International Working Group criteria were eligible.15 Patients with
acute promyelocytic leukemia and AML following a myeloproliferative disor-
der were not eligible. Patients with a prior history of myelodysplastic syndrome
were eligible if they progressed to AML without any prior therapy. Patients
with therapy-related AML were eligible provided the other treated malignancy
was in remission. CR had to be achieved after no more than two cycles of
induction chemotherapy. Up to two cycles of consolidation therapy could be
administered before transplantation. Induction and consolidation chemo-
therapy regimens were not defined by the study. Transplantation was required
within 6 months from initial documentation of morphologic CR. Additional
eligibility criteria are included in the Appendix (online only).
From January 2004 to April 2006, the initial study design included only
HLA-identical sibling donors, but in April 2006, the study was amended to
allow for enrollment of patients with volunteer unrelated donors con-
firmed to be matched at HLA-A, -B, -C, -DRB1, or -DQB1 by high-
resolution molecular typing.
Both patients and sibling donors gave written informed consent in ac-
cordance with the Helsinki protocol on a study approved by the institutional
review board at each participating institution. All unrelated donors included in
the study provided written informed consent for participation in Center for
International Blood and Marrow Transplant Research studies approved by the
National Marrow Donor Program institutional review board. The study was
monitored by the CALGB Data Safety and Monitoring Board.
Conditioning Regimen
All patients received a conditioning regimen consisting of fludarabine at
30 mg/m2 per day intravenously (IV) over 30 minutes for 5 days on days 7
through 3 and busulfan 0.8 mg/kg IV over 2 hours every 6 hours for 8 doses
on days 4 and 3. Included in the April 2006 amendment to allow unrelated
donors was the administration of rabbit antithymocyte globulin (ATG; thy-
moglobulin; sanofi-aventis, Cambridge, MA) at 2.5 mg/kg per day IV over 6
hours for 3 doses on days 4 through 2 to all patients regardless of donor
type. Eight recipients of HLA-matched sibling allografts were treated before
the amendment and did not receive ATG.
Donor Mobilization and Target Allograft Composition
Donors received granulocyte colony-stimulating factor 10 g/kg subcu-
taneously on days 5 through 2 (and on day 1, if necessary) and began
leukapheresis on transplantation days 1 and 0 (and on day 1, if needed) to
achieve a CD34 cell dose of 2 to 8  106 cells per kilogram (actual weight of
the recipient).
Supportive Care and Patient Assessments
Tacrolimus (target level, 5 to 10 ng/mL) and methotrexate (5 mg/m2 IV
days 1, 3, 6, and 11) were given for graft-versus-host disease (GVHD)
prophylaxis. Tacrolimus was to be tapered starting on day 90 in the absence
of active GVHD with a goal of tapering off completely by day 180. Granulo-
cyte colony-stimulating factor was given at 5 g/kg subcutaneously starting on
day 12 and was continued until neutrophil engraftment. Additional sup-
portive care details are included in the Appendix.
Acute GVHD (aGVHD) and chronic GVHD (cGVHD) were graded
according to established criteria.16,17 Patients were considered evaluable for
GVHD if they engrafted. Organ toxicity was graded according to the
National Cancer Institute Common Terminology Criteria for Adverse
Events version 3.0.
Definitions
Neutrophil engraftment was defined as an increase in the absolute neu-
trophil count to 500/L or greater for 3 consecutive days after a conditioning
regimen–induced nadir. Platelet engraftment was defined as the first day of
three consecutive platelet count measurements greater than 20,000/L with-
out the aid of transfusion for 7 consecutive days. Nonrelapse mortality (NRM)
was defined as death in continuous complete remission (CR). Primary graft
failure was defined as failure of neutrophil engraftment by day30. Secondary
graft failure was defined as primary engraftment followed by a subsequent
decline in the neutrophil count to less than 500/L without any apparent cause
(eg, drugs or opportunistic infection) and unresponsiveness to hematopoietic
growth factor therapy. Cytogenetic risk category was assigned based on the
CALGB criteria.18
Statistical Considerations
The primary end point of this single-arm phase II multicenter trial was
2-year DFS in the unrelated donor recipient group. We focused primarily on
the unrelated donor group because the majority of older patients require
unrelated donors. DFS time was measured as time from transplantation to
relapse or death as a result of any cause, censoring at loss to follow-up. A 2-year
DFS probability of 0.35 was considered sufficiently promising to proceed to a
phase III trial, and a probability of  0.20 was considered not promising,
based on CALGB historical data.19 Kaplan and Meier estimation was used to
determine survival probability.20 Power for rejecting Ho: DFS  0.20, calcu-
lated for a sample size of 61 patients under H1: DFS  0.35, was estimated as
84% at the   .05 level.
Secondary end points were rate of aGVHD at 100 days from transplan-
tation, relapse, NRM, rate of cGVHD, and overall survival (OS) at 2 years from
date of transplantation. Cumulative incidence curves were computed for time
to relapse, with NRM as a competing risk. Cumulative incidence of NRM was
computed with death as a result of relapse as a competing risk. Cumulative
incidence for GVHD was computed with death as a result of any cause as a
competing risk. OS was analyzed by using Kaplan and Meier estimation,
including death as a result of any cause. For all end points, median time to
event was estimated by using the Kaplan and Meier method.
After the study was amended to allow inclusion of patients receiving
transplantations from unrelated donors, univariable Cox proportional haz-
ards regression was used to test for differences in time-to-event end points
between patients receiving transplantations from related versus unrelated do-
nors (donor type).21 For the comparison analyses, patients experiencing a
competing risk event were treated as censored.
Univariable Cox proportional hazards models were also used to test
for the influence of a series of covariates on time-to-event end points by
using cause-specific hazards for outcomes with competing risks. Patient
age, sex, WBC count at diagnosis, cytogenetic risk category, time from
diagnosis to transplantation, time from achievement of CR to transplan-
tation, receipt of consolidation (yes/no), patient-donor sex matching,
ABO mismatch (match, minor mismatch, major mismatch), CD34 dose in
graft, CD3 dose in graft, receipt of ATG (yes/no), and donor type were
all considered. A detailed description of the methods for testing the
association of chimerism with time-to-event end points is provided in
the Appendix.
Data collection and statistical analyses were conducted by the Alli-
ance Statistics and Data Center. Data quality was ensured by review of data
by the Alliance Statistics and Data Center and by the study chairperson
Devine et al
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following Alliance policies. All analyses were based on the study database
(frozen on December 10, 2014). Data were downloaded and preprocessed
by using SAS version 9.3 (SAS Institute, Cary, NC).22 All statistical calcu-
lations were performed by using version 3.1.3 of the R software environ-
ment for statistical computing and its extension packages.23-27 Additional
information concerning these statistical approaches is provided in the
Appendix.
RESULTS
Patient and Donor Characteristics
Patient and donor characteristics are provided in Table 1. In all,
121 patients were registered and received transplantations at 21 cen-
ters between November 2004 and November 2011. Seven of the pa-
tients who received transplantations were excluded from the primary
analysis after they were deemed ineligible for the following reasons:
received three cycles of consolidation (one patient), beyond CR1 at
time of transplantation (one patient), lack of documentation of CR1
before transplantation (two patients), low diffusing capacity of lungs
for carbon monoxide (one patient), history of polycythemia vera (one
patient), and development of AML after therapy for myelodysplastic
syndrome (one patient). The remainder of the results pertain to the
114 eligible recipients. The median patient age was 65 years (range, 60
to 74 years) and was similar for recipients who had either related or
unrelated donors. The median time from diagnosis to transplantation
was 138 days (range, 61 to 265 days), and the median time from
achievement of CR1 to transplantation was 85 days (range, 9 to 184
days).
Engraftment and Chimerism
Twenty-two patients (19%) never developed a neutrophil nadir
below 500/L, and 54 (47%) never developed a platelet nadir below
20,000/L. Among patients who did develop neutropenia and/or
thrombocytopenia, the median time to neutrophil engraftment was
14 days (range, 1 to 22 days) and to platelet engraftment was 11 days
(range, 1 to 25 days) post-transplantation. No patients experienced
primary graft failure. Two patients developed secondary graft fail-
ure and both required second transplantations. Beginning with the
first planned sample on day 30, the median proportion of donor
cells in samples of peripheral blood analyzed for myeloid chimer-
ism was consistently higher than 98% (range, 50% to 100%) at all
time points analyzed. In contrast, mixed CD3 chimerism was
frequently observed. Median CD3 chimerism values gradually
increased over time in the surviving patients without relapse and
were 96% (range, 0% to 100%) at day 30, 95% (range, 7% to
100%) at day 90, 98% (range, 8% to 100%) at day 180, and
100% (range, 10% to 100%) at day 365. Table 2 summarizes the
observed CD3 cell chimerism levels at each time point in survi-
vors without relapse (graphically illustrated in Appendix Fig A1,
online only). There was no association between level of CD3
chimerism at any time point with relapse, DFS, or OS.
aGVHD and cGVHD
The cumulative incidences of grades 2 to 4 and 3 to 4 aGVHD
at 100 days were 9.6% (95% CI, 4% to 15%) and 2.6% (95% CI, 0%
to 6%), respectively, and did not differ by donor type (Fig 1). The
median time to onset of grade 2 to 4 aGVHD was 41 days (range, 4
to 79 days). The cumulative incidence of any cGVHD by 2 years
Table 1. Recipient and Donor Characteristics (N  114)
Characteristic
Result
No. (%) Median (range)








Complex (including 17p del) 26
del 7 only† 2
11q23 (not t(9;11)) 2
Other 2
Unknown 1 (1)
WBC at diagnosis,  103/mL 3.9 (0.4-333)
Antecedent hematologic disorder 20 (18)
One induction course 70 (61)






High-dose cytarabine based 48 (56)
Standard-dose cytarabine based
or other 37 (44)
Time from diagnosis to transplantation,
days 138 (61-265)
Time from CR1 documentation to




















Minor mismatch 22 (19)
Major mismatch 24 (21)
Unknown 2 (2)
Allograft composition
CD34 dose/kg ( 106) 6.2 (0.8-30.5)
CD3 dose/kg ( 108) 1.9 (0-5.1)
Abbreviations: CMV, cytomegalovirus; CR1, first complete response; MRD,
matched related donor; MUD, matched unrelated donor.
Complex, three or more cytogenetic abnormalities.
†17p del, deletion of the short arm of chromosome 17.
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was 28% (95% CI, 19% to 36%); cumulative incidence of extensive
cGVHD was 11% (95% CI, 5% to 16%) at 2 years. For all patients
experiencing limited or extensive cGVHD, the median time to
onset of cGVHD was 216 days (range, 99 to 806 days) post-
transplantation. Patients receiving ATG had a lower risk of
cGVHD (hazard ratio, 0.26; 95% CI, 0.11 to 0.64; P  .002). There
was no association between the other clinical variables analyzed,
including age and donor type and the risk of grades 2 to 4 aGVHD
or all stages of cGVHD (Table 3).
Nonhematologic Toxicity and Opportunistic Infections
Nonhematologic toxicity attributable to the conditioning regi-
men was generally mild to moderate and reversible. Although cumu-
latively, 68% of patients experienced at least one grade 3 to 5 toxicity,
the incidences of grade 3 to 5 organ toxicity (mucositis, other GI,
hepatic, pulmonary, renal, cardiac, and neurologic) were 5% or less in
each category. No cases of hepatic sinusoidal obstruction syndrome
were observed.
Reactivation of cytomegalovirus (viremia) occurred in 33 (41%)
of 81 donor/recipient pairs at risk, although nine patients (8%) expe-
rienced Epstein-Barr virus reactivation requiring treatment. No cyto-
megalovirus organ disease was observed, but two patients
developed Epstein-Barr virus–related post-transplantation lym-
phoproliferative disorder and died of causes secondary to related
complications.
NRM, Relapse, DFS, and OS
The median follow-up of the 43 surviving eligible patients was
1,602 days (range, 306 to 3,233 days). Eighteen patients (16%) died
from causes other than relapse at a median of 279 days (range, 41 to
949 days) after transplantation. The cumulative incidence of NRM at
2 years was 15% (95% CI, 8% to 21%; Fig 2A) and did not differ by
donor type; it was 13% (95% CI, 4% to 22%) for related versus 16%
(95% CI, 6% to 26%) for unrelated donor transplantations. Fifty-
seven patients relapsed at a median of 194 days (range, 15 to 2,041
days) after transplantation. The cumulative incidence of relapse for
the entire group was 44% (95% CI, 35% to 53%) at 2 years and did not
differ by donor type (Fig 2B). The DFS probability at 2 years after
transplantation was 42% (95% CI, 33% to 52%) for the entire group.
The DFS probabilities at 2 years for recipients of related and unrelated
transplantations were 43% (95% CI, 32% to 59%) and 40% (95% CI,
29% to 55%), respectively (P  .72; Figs 2C and 2D). Receipt of ATG
did not affect relapse or DFS. The observed 40% DFS (95% CI, 29% to
55%) in the unrelated donor group satisfied our prespecified criteria
for success. OS probability at 2 years was 48% (95% CI, 39% to 58%)
for the entire group, 45% (95% CI, 34% to 61%) for recipients of
related donor transplantations, and 50% (95% CI, 38% to 64%) for
recipients of unrelated donor transplantations (P  .80; Figs 2E and
2F). When we reanalyzed the data and included the seven patients who
were deemed to be ineligible post hoc, there were no significant differ-
ences in DFS or OS between the 121 total versus 114 eligible patients
(Appendix Table A1, online only). Of the 43 surviving patients, at least
31 (72%) were known to not be receiving any type of immunosup-
pressive therapy at last follow-up. The median OS for those patients
who relapsed post-transplantation was 136 days (95% CI, 107 to 198
days). Cytogenetic risk category did not significantly influence the risk
of relapse, DFS, or OS (Table 3 and Appendix Fig A2, online only).
Additional information about the relapsing patients is provided in
the Appendix.
Seventy-one patients have died. As shown in Table 4, relapse
was the most common cause of death (n  53), representing 75%
of all deaths.
DISCUSSION
This prospective trial demonstrates that RIC HSCT from HLA-
matched donors is feasible and effective in older patients with AML
in CR1. The rate of NRM is comparable to that reported in studies
involving younger patients and suggests that assessment of physi-
ologic status is a more informative criterion for transplantation
eligibility than chronologic age.28-30 Of critical importance, for the
first time (to the best of our knowledge), favorable results in
transplantation of older patients have been obtained in a multi-
center cooperative group setting, which makes the results more
likely to be generalizable. The results are similar to those in previ-
ous single-institution prospective and retrospective studies involv-
ing older patients with AML.19,31-35 The 2-year DFS and OS rates in
this group compare favorably to those in studies of conventional
chemotherapy– based approaches to remission consolidation in
which DFS and OS rates beyond 2 years are typically below 20%.
We note that this was not a comparative trial, and the rate of
accrual was relatively slow (two to three patients per month) while
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Fig 1. Cumulative incidence of grades 2 to 4 and grades 3 to 4 acute
graft-versus-host disease in all patients regardless of donor type.
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Fig 2. Cumulative incidence of (A) nonrelapse mortality by donor type and (B) relapse by donor type. Kaplan-Meier estimates of (C) disease-free survival for all
patients, (D) disease-free survival by donor type, (E) overall survival for all patients, and (F) overall survival by donor type. MRD, matched related donor; MUD, matched
unrelated donor.
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the study was open to accrual, suggesting that patients involved
in this study were a selected group. The possible selection biases
inherent in such a trial should be considered when analyzing
these results.
Relapse remains the major barrier to successful outcome after
transplantation, regardless of patient age. The 44% relapse rate at 2
years was high, although relapse rates approaching 80% to 90%
have been observed in older patients after conventional chemo-
therapy, suggesting a potential graft-versus-leukemia effect.2-6 In-
terpretation of our trial results is limited somewhat by lack of
consistent knowledge of the mutational status of the patients at
diagnosis or of disease burden at CR by minimal residual disease
assessment. Interestingly, cytogenetic results did not appear
to influence clinical outcomes in this data set. Our trial may
have included better-risk patients, although 28% harbored a
poor-risk karyotype at diagnosis, and 18% had an antecedent
hematologic disorder or treatment-related AML.36,37 Future
transplantation studies should make every effort to incorporate
molecular characterization at diagnosis in these patients to
better understand the role of transplantation in specific molec-
ular subgroups. Nonetheless, relapse remains the primary cause
of death in these patients, and efforts to prevent its development
after transplantation are imperative for building on these en-
couraging results.
The rates of aGVHD and cGVHD observed on this trial were
actually lower than originally anticipated. The study was initiated
before the 2005 National Institutes of Health consensus panel on
cGVHD, so the older cGVHD classification scheme was used.17
Only 13% of patients experienced extensive cGVHD by using this
classification, which is somewhat lower than rates reported in other
studies.38,39 The incorporation of rabbit ATG into the condition-
ing regimen for all patients, including recipients with matched
sibling donors, may have contributed to the relatively low rates of
GVHD and NRM, as has been observed in previous studies.38,40
However, ATG use at this relatively high dose may also have
contributed to more relapses after the RIC regimen, consistent
with retrospective data reported by the Center for International
Blood and Marrow Transplant Research.41 Whether ATG should
be incorporated into the GVHD prophylaxis regimen for these
patients remains an open question.
How should these results be interpreted in comparison to con-
ventional consolidation therapy? Given multiple potential biases
among leukemia therapists and their patients, a truly randomized
study comparing transplantation to chemotherapy seems unlikely
because of the lack of equipoise. The preliminary results of a random-
ized phase III trial performed in Germany (NCT00766779; HCT
Versus CT in Elderly AML) were recently reported in abstract form
and showed a significant advantage in leukemia-free survival for
patients receiving an allograft.42 The results of that study and ours
suggest that another randomized study in this setting may not be
feasible or even necessary. Another National Cancer Institute–
sponsored trial in older patients with AML that incorporated
HSCT into the study (ECOG-E2906/NCT02085408; Clofarabine
or Daunorubicin Hydrochloride and Cytarabine Followed By De-
citabine or Observation in Treating Older Patients With Newly
Diagnosed Acute Myeloid Leukemia) is ongoing, and the results
are pending. Patients who receive transplantation are certainly a
selected group. A donor-versus-no-donor analysis is the only way
to fairly compare the two approaches, but the successful use of
unrelated donors and availability of alternative donors (eg, umbil-
ical cord blood, haploidentical related) would collapse the size of
the no-donor group and make such a design difficult to complete.
The results of this trial create a platform on which future trials
can build. Studies to more precisely define the physiologic charac-
teristics that determine a patient’s suitability for transplantation
are needed. Methods to assess minimal residual disease before and
after transplantation should be explored, as should strategies to
prevent relapse after transplantation. Notwithstanding, these re-
sults demonstrate that for the foreseeable future, RIC HSCT has an
established role as a consolidative strategy for selected older pa-
tients with AML in CR1. Studies are needed to better define the
group of older patients with AML most likely to benefit from this
approach.
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Table 4. Causes of Death
Cause No. (%)
Relapse 53 (74.6)
aGVHD related 3 (4.2)
cGVHD related 6 (8.5)
PTLD 2 (2.8)
Sepsis 1 (1.4)
Secondary graft failure 1 (1.4)
Rectal cancer 1 (1.4)
Pneumonia 1 (1.4)
Pneumonitis 1 (1.4)
HHV-6 encephalitis 1 (1.4)
Sudden death 1 (1.4)
Abbreviations: aGVHD, acute graft-versus-host disease; cGVHD, chronic
graft-versus-host disease; HHV-6, human herpes virus 6; PTLD, post-
transplantation Epstein-Barr virus–related lymphoproliferative disorder.
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GLOSSARY TERMS
Allogeneic stem cell transplant: the transplantation of
multipotent hematopoietic stem cells, usually derived from bone
marrow, peripheral blood, or the umbilical cord blood of a genet-
ically nonidentical human donor.
CD34: an antigen selectively expressed on human lymphoid
and myeloid hematopoietic progenitor cells. CD34 is also ex-
pressed on vascular endothelium.
Cumulative incidence: a statistical measure of an event of interest
(eg, relapse, death, second malignant neoplasm, a specific disease) oc-
curring in a specified period of time in the population at risk. It is calcu-
lated by using the formula: (number of new cases of the event of
interest)/(total population at risk).
Disease free survival: the survival period spanning the time from
surgery to a recurrence of cancer.
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In addition to the patient eligibility criteria outlined in the article, eligible patients had to have an Eastern Cooperative Oncology
Group performance status between 0 and 2, a diffusing capacity of the lungs for carbon monoxide of more than 40% on pulmonary
function testing, a left ventricular ejection fraction of  30% on echocardiogram or multiple gated acquisition scan, no active serious
infection requiring antibiotics, no uncontrolled diabetes mellitus, no evidence of exposure to HIV, bilirubin less than 2 mg/dL, AST level
less than 3 upper limit of normal, and a calculated creatinine clearance  40 mL/min.
Donor Mobilization and Target Allograft Composition
If the yield of CD34 cells during donor mobilization was less than 2  106/kg on day 1, an additional leukapheresis was performed
on day 0 to achieve a targeted total dose of 2 to 8  106/kg CD34 cells.
Supportive Care and Patient Assessments
Blood cytomegalovirus surveillance was performed once per week through day100, and preemptive treatment was given according
to institutional guidelines. Surveillance for Epstein-Barr virus (EBV) infection was performed once every 2 weeks from neutrophil
engraftment by using a real-time quantitative EBV DNA polymerase chain reaction plasma-based assay through day 100. Patients who
developed blood EBV DNA concentration of more than 1,000 copies per milliliter on any two consecutive tests were recommended to
receive preemptive rituximab at 375 mg/m2 for at least one dose.
Donor hematopoietic chimerism was assessed on samples of separated T cells (CD3) and myeloid cells (CD15 or CD33) from
peripheral blood obtained on or around days 30, 90, 180, and 365 by using methods that were available at each institution.
Statistical Considerations and Study Design
In all, 121 patients were registered and received transplantations at 21 centers between November 2004 and November 2011. The
study was amended in April 2006 to allow for the inclusion of patients receiving transplantation from unrelated donors. In the original
design, the primary end point was to estimate disease-free survival (DFS) in recipients of both matched sibling and matched unrelated
donor transplantation. The power estimates projected that a total of 61 patients would be required. When that accrual total was met, the
study was temporarily suspended on December 29, 2008, and amended so that the primary analysis would be to estimate DFS in the
recipients of unrelated donor transplantations only. The rationale at the time was that most of these older patients with acute myeloid
leukemia would require volunteer unrelated donors to receive a transplantation. The study was reopened on November 2, 2009, and
completed accrual in November 2011 after a sufficient number of unrelated donor recipients had been registered.
Acute Graft-Versus-Host Disease Censoring
For cumulative incidence and cause-specific hazard analyses of acute graft-versus-host disease (aGVHD), censoring was imposed at
100 days post-transplantation. Any patients not experiencing aGVHD (or one of the competing risks) within 100 days of transplantation
was treated as censored at 100 days in the analysis, regardless of whether or not they experienced aGVHD at a later time. All other
time-to-event and cumulative incidence analyses were based on censoring resulting from loss to follow-up.
Chimerism Models
For the chimerism analyses, the missing data on patient chimerism measurements was assumed to be noninformative. Association of
chimerism with time-to-event end points was tested by using cause-specific hazards. Univariable Cox proportional hazards regression was
used to test for association of time-to-event end points with the chimerism level at 30, 90, 180, or 365 days.
In addition, joint models for longitudinal and time-to-event data were used to test for association between outcomes and chimerism
as a time-dependent variable (Rizopoulos D: Joint models for longitudinal and time-to-event data: With applications in R. Boca Raton,
FL, CRC Press, 2012). First, a linear mixed effect model was fit to the longitudinal chimerism data with days since transplantation and the
interaction of donor type and days since transplantation as fixed effects and days since transplantation as a random effect. Next, a Cox
model was fit to the time-to-event outcome with donor type as a covariate by using cause-specific hazards for outcomes with competing
risks. Finally, a survival model with a piece-wise constant baseline risk function was fit to the time-to-event outcome, with donor type as
a time-independent covariate and chimerism level as estimated in the longitudinal model as a time-dependent variable. The baseline risk
was approximated for intervals between six internal knots at evenly spaced percentiles across the observed event times. The analyses were
conducted first for all patients with chimerism data and again limited to only those patients with chimerism data at two or more time
points.
Covariate Analysis
Univariable Cox proportional hazards models were used to test for the influence of a series of covariates on time-to-event end points
by using cause-specific hazards for outcomes with competing risks. For categorical variables, values of “unknown” were treated as
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missing. For the cytogenetic risk category, only one patient was categorized as “favorable,” so the cells for “favorable” and
“intermediate” were combined. Antithymocyte globulin (ATG) administration status was determined by patient registration date,
with patients registered before the amendment allowing for unrelated donors assumed not to have received ATG, and those
registered following the amendment assumed to have received it.
Overall Survival and DFS
In addition to the analyses described in the article, the overall survival (OS) and DFS analyses were repeated for all patients who
received transplantations, including those deemed ineligible.
Results
Low Doses of Transplanted CD34 Cells and Secondary Graft Failure
There were three patients who received transplanted CD34 cell doses below the target of 2.0  106/kg. All three engrafted and did
not develop late graft failure. Secondary graft failure was observed in two patients who received CD34 cell doses of 4.9 and 6.6 106/kg,
respectively.
OS and DFS
Appendix Table A1 shows that the OS and DFS results for the analysis population are similar to those for all patients who received a
transplantation. The inclusion of the seven ineligible patients changes OS and DFS at 2 years by only approximately 1% and changes
median survival times by less than 2 months.
We also analyzed DFS and OS by cytogenetic risk category. The one patient with favorable cytogenetics did not relapse. Of the 80
patients with intermediate risk and 32 with adverse risk cytogenetics, 37 and 19 relapsed, respectively. DFS and OS by cytogenetic category
are depicted in Appendix Fig A2. The differences are not statistically significant.
Treatment and Survival of Relapsed Patients
Data were reported on 42 patients who received nonprotocol therapy for relapsed acute myeloid leukemia. Of these, 16 received
conventional chemotherapy–based treatment, 16 hypomethylating agent–based treatment, six investigational agents, two intrathecal
chemotherapy only, one donor lymphocyte infusion (DLI) only, and one unknown. Five of the patients who received some form of
chemotherapy for relapse also received a DLI. Twenty relapsed patients survived 6 months or longer after relapse, 10 patients survived at
least 1 year after relapse, and three patients were surviving 2 years after relapse. In total, four of the 57 relapsed patients were still alive at last
follow-up, and one of these survived beyond 2 years of last follow-up.
Eight patients, all of whom had received ATG, received a DLI either alone or following re-induction chemotherapy. Three patients
received a DLI for poor donor chimerism without overt evidence of relapse. The median survival of these eight patients was 201 days
(range, 63 to 1,017 days). All have died.
Of the original eight recipients of matched sibling donor transplantation who did not receive ATG, seven had intermediate-risk and
one had adverse risk cytogenetics. Of these eight, two relapsed, four died from nonrelapse mortality as a result of complications of aGVHD
or chronic GVHD, and two became long-term disease-free survivors.
Institutions That Participated in the Study
The following institutions participated in this study: Christiana Care Health Services Community Clinical Oncology Program,
Wilmington, DE (Stephen Grubbs, MD, supported by CA45418); Dana-Farber Cancer Institute, Boston, MA (Harold J. Burstein, MD,
PhD, supported by CA32291); Massachusetts General Hospital, Boston, MA (Jeffrey W. Clark, MD, supported by CA32291); Mount Sinai
School of Medicine, New York, NY (Lewis R. Silverman, MD, supported by CA04457); Monter Cancer Center of North Shore-Long
Island Jewish Health Systems, Lake Success, NY (Daniel Budman, MD, supported by CA35279); Roswell Park Cancer Institute, Buffalo,
NY (Ellis Levine, MD, supported by CA59518); The Ohio State University Medical Center, Columbus, OH (Clara D. Bloomfield, MD,
supported by CA77658); University of California at San Francisco, San Francisco, CA (Charles J. Ryan, MD, supported by CA60138);
University of Maryland Greenebaum Cancer Center, Baltimore, MD (Martin Edelman, MD, supported by CA31983); University of
Minnesota, Minneapolis, MN (Bruce A. Peterson, MD, supported by CA16450); University of North Carolina at Chapel Hill, Chapel Hill,
NC (Thomas C. Shea, MD, supported by CA47559); Washington University School of Medicine, St. Louis, MO (Nancy Bartlett, MD,
supported by CA77440); and Weill Medical College of Cornell University, New York, NY (John Leonard, MD, supported by CA07968).
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Table A1. OS and DFS
Analysis No. of Patients No. of Events Percent Survival at 2 Years Median of Years for OS or DFS 95% CI
OS 114 71 47.5 1.93 1.37 to 3.32
OS MRD 55 34 45.3 1.62 1.26 to NA
OS MUD 59 37 49.6 1.97 1.34 to 3.74
OS, all 121 76 47.3 1.89 1.36 to 3.32
OS MRD, all 58 36 46.4 1.78 1.26 to NA
OS MUD, all 63 40 48.0 1.89 1.31 to 3.74
DFS 114 75 41.5 1.26 0.83 to 2.25
DFS MRD 55 36 43.3 1.26 0.71 to 4.87
DFS MUD 59 39 39.7 1.12 0.83 to 2.36
DFS, all 121 80 40.4 1.12 0.81 to 2.14
DFS MRD, all 58 38 42.2 1.26 0.71 to 4.87
DFS MUD, all 63 42 38.8 1.04 0.77 to 2.24
NOTE. The term “all” signifies all patients who received a transplantation.
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Fig A1. CD3 cell chimerism levels in surviving patients without relapse by time point. Thick bars represent median values; thin bars indicate 95% CIs.
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Fig A2. (A) Disease-free survival and (B) overall survival by cytogenetic risk category.
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